Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus LIQUID E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus LIQUID E Z PAQUE.
HYPAQUE-M,90% vs LIQUID E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Renal: >95% unchanged; biliary/fecal: <5%
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent